Venture capital-backed biopharmaceutical company Auspex Pharmaceuticals has priced its IPO on the Nasdaq exchange at $12 per share.
Auspex will offer 7m shares worth a total $84m, the company said in a statement.
The underwriters including Stifel and BMO Capital Markets will also have a 30-day option to acquire just over 1m shares to cover any over-allotments.
The company’s lead candidate is SD-809, is in a Phase 3 registration clinical trial for the treatment of chorea associated with Huntington’s disease. Its backers include Deerfield Management Company, Thomas, McNerney and Partners, CMEA Capital, Panorama Capital, BioMed Ventures and Costa Verde Capital.
Copyright © 2014 AltAssets